Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry
Dec 27, 2015
Nathan Tinker
Executive Director
New York Biotechnology Association
New York BizBio 2009
Fighting for a Healthy Biotech Industry
NYBA the voice of New York’s bioscience industry
• 250 member companies• Advocacy
– Public Policy– Annual Bio Advocacy Day– Relationships with State and Federal delegations
• Networking– Annual Meeting (April 20-21, NYC)– NewX2 Biocruise (June 19)– Regional events– LinkedIn community
• Information– State of the Industry Report– Website– Member news– Industry and competitive intelligence
Why is bioscience important to New York?
ResearchDiscovery
TechnologyTransfer &Business
Development
New Medical Devices,
Tests, Drugs & RelatedServices
Better Health Care,
Health & Quality of Life
NewJobs
New York bioscience is . . . business
746 establishmentsbiotechnology
medical devices
medicinal botanicalmanufacturing
pharmaceutical preparationmanufacturing
in-vitro diagnosticsubstance manufacturingbiological product
manufacturing
life sciences research
New York bioscience is . . . economic impact
$16 billionin direct economic output
$29 billionin total economic output
New York bioscience is . . . wages
$3.8 billionin direct wages
• Total biomedical wages in New York rose 16.9% 2003-2006
% Change
Drug & Chemical Mfg 13.8%
Labs & Research 17.1%
Med Equip & Supplies 22.3%
Critical requirements
• Discovery, Innovation and Technology DevelopmentState funding to fill gap in shrinking federal support of scientific innovation and new
technology development
• Financing, Investment and Business DevelopmentFunding and business resources to support early-stage corporate development in
the capital-intensive life sciences industry
• Facilities, Incubation and ExpansionAppropriate facilities (lab space, prototyping, & manufacturing) and infrastructure to
support nascent and expanding companies
• Workforce, Training and EntrepreneurshipInstitutional- and community-based initiatives to continue expanding skilled, multi-
disciplinary workforce to support industry growth
• Taxes, Incentives and Quality of LifePro-business programs and incentives – and program application assistance- to
improve economic conditions for new and expanding companies and their employees
• Marketing, Outreach and Strategic NetworkingStatewide, asset- and opportunity-driven attraction and retention plan
Massachusetts’s loss, New York’s gain?
• Boston Globe, Jan 22 & 28
Recent Massachusetts legislation, aimed at promoting cost containment and transparency in health care, included a provision that would forbid any kind of payments from biopharma companies or medical device manufacturing companies to a doctor in the State of Massachusetts, including clinical trials and other vital research.
Result: • MA companies have begun looking elsewhere.• Major conventions have cancelled contracts.
How can Albany help?
• Maintain a supportive regulatory environment
• Protect patient access to drugs, devices and therapeutics
• Expand the QETC
• Provide full funding the Empire State Stem Cell Initiative
Facts to remember
• 55,000+ direct jobs
• 75,000+ indirect/induced jobs
• $16 billion in direct economic impact
• $121 million in state taxes
• $3.8 billion in direct wages
• 6.8% of all direct biopharmaceutical output nationally
Nathan Tinker
NYBA
www.nyba.org
(631) 444-8895
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.